Dr. Lambert Edelmann is an intellectual property professional with extensive expertise in business transactions within the biotech and healthcare industry. With a doctorate in Cell Biology and more than 15 years of experience in patent law, Dr. Edelmann specializes in filing, managing, and prosecuting United States and international patents for life sciences.

Dr. Edelmann previously served as an Adviser at Entrepreneurship Lab (ELabNYC), a position he held since 2012, where he advised biotech startups on intellectual property strategy and business development. He recently served as Director of Business Development at Click Therapeutics, where he built and managed relationships with pharmaceutical companies in oncology and neurology to promote digital therapeutics as companions to pharmacotherapeutics.

Dr. Edelmann also was Associate Director of External Innovation and Alliance Management at PTC Therapeutics, where he provided strategic direction for business development, sourced and evaluated emerging technologies across multiple therapeutic areas, and managed a global portfolio of alliances and collaborations. During 2021-2022, he simultaneously served as Executive-in-Residence at Kairos Ventures, analyzing projects in ophthalmology and spinal cord injury for early-stage Venture Capital decision-making.

Formerly, Dr. Edelmann was Director of Scientific Business Development at the New York Blood Center, managing the company’s patent portfolio in cell therapy, oncology, infectious diseases, immunology, and hematology. As Business Development Director at Mount Sinai Innovation Partners, he managed intellectual property portfolios in neurology, oncology, and genome-guided drug discovery, and played a crucial role in the launch of Sema4, a genomics and precision medicine startup.

Earlier in his career, Dr. Edelmann worked at Massachusetts General Hospital (MGH) at Partners Healthcare as Senior Business Strategy and Licensing Manager, where he led external patent counsel in drafting, filing, and prosecuting more than 200 United States and international patent families, and directed business development strategy, technology evaluation, and commercialization.

Dr. Edelmann received his Ph.D. in Cell Biology from Eberhard Karls Universität Tübingen, Germany, and completed postdoctoral training in Genetics as a Human Frontiers Fellow at BioZentrum in Basel and later at MGH Cancer Center in Boston. His expertise in intellectual property, business transactions, and life sciences has enabled him to successfully foster innovation and growth across the biotech and healthcare sectors.

Education

  • Eberhard Karls Universität Tübingen, Germany, Ph.D., Cell Biology
  • BioZentrum, Basel, CH, and MGH Cancer Center, Boston, MA, Postdoctoral Training in Genetics, Human Frontiers Fellow
  • Yale School of Medicine, New Haven, CT, Yale Student Research Fellow in Cell Biology & Pharmacology, HHMI
  • Rutgers Business School, Mini MBA Bio Pharma Innovation
  • Wharton School of the University of Pennsylvania, Introduction to Financial Accounting
  • Wharton School of the University of Pennsylvania, Introduction to Marketing